XERIS PHARMACEUTICALS INC
NASDAQ: XERS (Xeris Biopharma Holdings, Inc.)
最近更新时间: 5小时之前7.45
-0.22 (-2.87%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Drug Manufacturers - Specialty & Generic (US) | 混合的 | 看涨 |
| Drug Manufacturers - Specialty & Generic (全球的) | 混合的 | 看涨 | |
| 股票 | Xeris Biopharma Holdings, Inc. | 混合的 | 看涨 |
AIStockmoo 评分
| 分析师共识 | NA |
| 内部交易活动 | -1.5 |
| 价格波动 | 2.0 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | -0.5 |
| 平均 | 0.25 |
|
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol. |
|
| 部门 | Healthcare |
| 行业 | Drug Manufacturers - Specialty & Generic |
| 投资方式 | Small Growth |
| 内部持股比例 | 4.19% |
| 机构持股比例 | 54.46% |
| 名称 | 平均购买 ($) | 平均卖出 ($) | 总净额 | 总净值 ($) |
|---|---|---|---|---|
| HECHT BETH | - | 8.43 | -16,666 | -140,494 |
| MCCULLOCH KEVIN | - | 8.43 | -15,000 | -126,450 |
| PIEPER STEVEN | - | 8.43 | -5,000 | -42,150 |
| 累积净数量 | -36,666 | |||
| 累积净值 ($) | -309,094 | |||
| 累积平均购买 ($) | - | |||
| 累积平均卖出 ($) | 8.43 | |||
| 名称 | 持有人 | 日期 | 类型 | 数量 | 价格 | 价值 ($) |
|---|---|---|---|---|---|---|
| PIEPER STEVEN | 职员 | 01 Sep 2026 | 自动卖出 (-) | 5,000 | 8.43 | 42,150 |
| HECHT BETH | 职员 | 01 Sep 2026 | 自动卖出 (-) | 16,666 | 8.43 | 140,494 |
| MCCULLOCH KEVIN | 职员 | 01 Sep 2026 | 自动卖出 (-) | 15,000 | 8.43 | 126,450 |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合